Akari Therapeutics PLC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Dr. Ray Prudo and affiliated entities have increased their beneficial ownership in Akari Therapeutics Plc to 8.9% following recent private placement transactions.
NASDAQ
Samir R. Patel and PranaBio Investments LLC have increased their beneficial ownership in Akari Therapeutics Plc to 10.4% following a private placement.
NASDAQ
SCHEDULE 13D/A: Akari Therapeutics' Major Shareholder Dr. Ray Prudo Boosts Stake to 9.3% Following Private Placement
Dr. Ray Prudo, a key reporting person, has increased his beneficial ownership in Akari Therapeutics, Plc to 9.3% of outstanding Ordinary Shares following participation in a December 2024 private placement.